title: Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance.
abstract: Avitinib, a new generation inhibitor of epidermal growth factor receptor (EGFR), was approved for clinical trial in both China and the United States, and the phase 1 trials were initiated in both countries in parallel. In the preclinical studies, avitinib showed three novel features including (1) irreversibly binding EGFR by forming a covalent bound with Cys 797 in the ATP-binding pocket, (2) sparing wild-type EGFR, and (3) overcoming T790M-induced resistance. Avitinib is the first China-developed novel EGFR inhibitor that has entered in global clinical trials, and will provide a precision targeted therapy for non-small cell lung cancer patients.
authors.affiliation: ACEA Biosciences Inc., San Diego, CA, 92121, USA. xxu@aceabio.com.|ACEA Pharmaceutical Research, Hangzhou, Zhejiang, 310030, P. R. China. xxu@aceabio.com.
authors.forename: Xiao
authors.initials: X
authors.lastname: Xu
mesh_terms: D000970:Antineoplastic Agents; D002289:Carcinoma, Non-Small-Cell Lung; D002681:China; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors; D006801:Humans; D008175:Lung Neoplasms; D015337:Multicenter Studies as Topic; D009154:Mutation; D010597:Pharmacogenetics; D057285:Precision Medicine
chemical_list: D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors